Notably, when combined with immune checkpoint inhibitors, FSP1 inhibitors have shown enhanced anti-tumor immunity and reduced tumor growth in mouse models, highlighting their potential in combination therapies. The gene discussed is AIFM2; the disease is neoplasm.